Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Senores Pharmaceuticals Ltd. ( (IN:SENORES) ) has provided an announcement.
Senores Pharmaceuticals Limited announced the acquisition of the USFDA-approved Abbreviated New Drug Application (ANDA) for Roflumilast tablets, used to treat severe Chronic Obstructive Pulmonary Disease (COPD) with chronic bronchitis. This acquisition, funded through the company’s IPO proceeds, aligns with Senores’ strategic focus on expanding its presence in the chronic bronchitis therapy area while enhancing its portfolio in specialty distribution.
More about Senores Pharmaceuticals Ltd.
Senores Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and distribution of generic pharmaceuticals. The company aims to expand its portfolio into specialty distribution, particularly in niche and under-penetrated generic formulations, addressing unmet healthcare needs.
YTD Price Performance: -9.73%
Average Trading Volume: 143,978
For an in-depth examination of SENORES stock, go to TipRanks’ Stock Analysis page.